Molecular targeted therapy in recurrent glioblastoma: Current challenges and future directions

Expert Opinion on Investigational Drugs

Volumn 21, Issue 9, 2012, Pages 1247-1266

  Patel, Mital ^a   Vogelbaum, Michael A ^a   Barnett, Gene H ^a   Jalali, Rakesh ^b   Ahluwalia, Manmeet S ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TATA MEMORIAL HOSPITAL   (India)

^c Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center   (United States)

Author keywords

Bevacizumab; EGFR; Glioblastoma; Molecular targeted therapy; Monoclonal antibodies; Multikinase inhibitors; PDGF; Signaling pathways; Tyrosine kinase inhibitors; VEGF

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; AFATINIB; BEVACIZUMAB; BRIVANIB; BUPARLISIB; CABOZANTINIB; CEDIRANIB; CETUXIMAB; CYTOTOXIC AGENT; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FORETINIB; GEFITINIB; HEAT SHOCK PROTEIN; ICRUCUMAB; INDETANIB; LAPATINIB; LENVATINIB; MK 0752; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; MONOCLONAL ANTIBODY I 125; NIMOTUZUMAB; PAZOPANIB; PROTEASOME; RAMUCIRUMAB; RO 4829097; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VATALANIB; VELIPARIB; VISMODEGIB; XL 147; XL 765;

CANCER GENETICS; CANCER SURVIVAL; DRUG APPROVAL; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MOLECULAR GENETICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG DESIGN; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SURVIVAL;

EID: 84865310348     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.703177     Document Type: Review

References (168)

1. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004 - 2007. Available from: www. cbtrus.org 2011
2. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401
3. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004;6(3):227-35 (Pubitemid 39136506)
4. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien) 2011;153(6):1211-18
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96 (Pubitemid 40349501)
6. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352(10):997-1003 (Pubitemid 40349502)
7. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10(5):459-66
8. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11(2):165-80 (Pubitemid 43261763)
9. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10(2):162-70
10. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17(8):2572-8 (Pubitemid 29368260)
11. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70(10):779-87
12. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83(5):588-93 (Pubitemid 30636298)
13. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-40.
14. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-5
15. Sathornsumetee S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer 2007;110(1):13-24
16. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64(6):479-89 (Pubitemid 40781150)
17. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006;66(23):11502-13 (Pubitemid 46009984)
18. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
19. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63(7):1602-7 (Pubitemid 36373650)
20. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102(16):5814-19 (Pubitemid 40559642)
21. The TCGA research network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455(7216):1061-8
22. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2(2):127-37 (Pubitemid 33674041)
23. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11(4):1462-6 (Pubitemid 40315227)
24. Agosti RM, Leuthold M, Gullick WJ, et al. Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch A Pathol Anat Histopathol 1992;420(4):321-5
25. Huang HS, Nagane M, Klingbeil CK, et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 1997;272(5):2927-35 (Pubitemid 27053343)
26. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25(16):2288-94 (Pubitemid 46954657)
27. Nishikawa R, Ji XD, Harmon RC, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 1994;91(16):7727-31 (Pubitemid 24238258)
28. Ye F, Gao Q, Cai MJ. Therapeutic targeting of EGFR in malignant gliomas. Expert Opin Ther Targets 2010;14(3):303-16
29. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63(20):6962-70 (Pubitemid 37322983)
30. Chakravarti A, Chakladar A, Delaney MA, et al. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62(15):4307-15 (Pubitemid 34827287)
31. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal-growthfactor- receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;56(1):72-7 (Pubitemid 24044796)
32. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57(21):4838-48 (Pubitemid 27468992)
33. Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cell by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc Am Soc Clin Oncol 2002;21:abstr 79
34. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98(1):93-9
35. Vogelbaum MA, Peereboom D, Stevens G, et al. Response rate to single agent therapy with the EGFR tyrosine kinase inhibitor erlotinib in recurrent glioblastoma multiforme: results of a phase II study [abstract TA-59]. Proceedings of the Ninth meeting of the Society for Neuro-Oncology; 2004. p. 384
36. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009;27(8):1268-74
37. Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 2010;12(1):95-103
38. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004;22(1):133-42 (Pubitemid 41095125)
39. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22(16):3238-47 (Pubitemid 41103678)
40. Haas-Kogan DA, Prados MD, Lamborn KR, et al. Biomarkers to predict response to epidermal growth factor receptor inhibitors. Cell Cycle 2005;4(10):1369-72 (Pubitemid 41437124)
41. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005;97(12):880-7 (Pubitemid 41417939)
42. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353(19):2012-24 (Pubitemid 41609094)
43. Rich JN, Reardon DA, Quinn JA, et al. A phase I trial of gefitinib (ZD1 839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol 2005;23(Suppl 1, Part 1):130S-S
44. Eisenstat DD, Nabors LB, Mason WP, et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. ASCO; Chicago; 2011
45. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006;66(24):11840-50 (Pubitemid 46094196)
46. Fukai J, Nishio K, Itakura T, et al. Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. Cancer Sci 2008;99(10):2062-9
47. Eller JL, Longo SL, Kyle MM, et al. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo. Neurosurgery 2005; 56(1):155-62; discussion 62 (Pubitemid 40054001)
48. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol 2009;20(9):1596-603
49. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12(5):508-16
50. Hasselbalch B, Eriksen JG, Broholm H, et al. Prospective evaluation of angiogenic, hypoxic and EGFR-related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 2010;118(8):585-94
51. Combs SE, Heeger S, Haselmann R, et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-phase I/II trial: study protocol. BMC Cancer 2006;6:133
52. Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009;9(9):1199-206
53. Bode U, Buchen S, Warmuth-Metz M, et al. Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S Suppl):2006
54. Massimino M, Bode U, Biassoni V, et al. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011;11(2):247-56
55. Yang W, Barth RF, Wu G, et al. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. Appl Radiat Isot 2009;67(7-8 Suppl):S328-31
56. Ostman A. PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15(4):275-86 (Pubitemid 38781051)
57. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: north American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006;12(16):4899-907 (Pubitemid 44338577)
58. Raymond E, Brandes AA, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008;26(28):4659-65
59. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23(36):9359-68
60. Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009;101(12):1995-2004
61. Dresemann G.. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005;16(10):1702-8 (Pubitemid 41510147)
62. Ahluwalia MS, de Groot J, Liu WM, et al. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 2010;298(2):139-49
63. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007;8(8):610-22 (Pubitemid 47093931)
64. Ahluwalia MS, Gladson CL. Progress on antiangiogenic therapy for patients with malignant glioma. J Oncol 2010;2010:689018
65. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn 2004;231(3):474-88 (Pubitemid 39410882)
66. Hillen F, Griffioen AW. Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007;26(3-4):489-502 (Pubitemid 350115123)
67. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001;11(3):293-9 (Pubitemid 32480296)
68. Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20(4):158-63
69. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6(5):507-16 (Pubitemid 39469986)
70. Lino MM, Merlo A, Boulay JL. Notch signaling in glioblastoma: a developmental drug target? BMC Med 2010;8:72
71. Dvorak HF. Vascular permeability factor/ vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20(21):4368-80 (Pubitemid 35266299)
72. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27(15):2542-52
73. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006;66(16):7843-8 (Pubitemid 44299144)
74. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42 (Pubitemid 38702844)
75. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34 (Pubitemid 36910021)
76. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003;97(9 Suppl):2381-6 (Pubitemid 36444049)
77. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-9 (Pubitemid 46424067)
78. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25(30):4722-9 (Pubitemid 350086473)
79. Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005;7:369
80. Gilbert MR, Wang M, Aldape K, et al. RTOG 0625: a randomized Phase II trial of bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). Neuro Oncol 2010;12(Suppl 4):iv36-57
81. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 2010;12(12):1300-10
82. Kang TY, Jin T, Elinzano H, et al. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neuro Oncol 2008;89(1):113-18
83. Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009;23(5):289-304
84. Gomez-Manzano C, Holash J, Fueyo J, et al. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 2008;10(6):940-5
85. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium Study. J Clin Oncol 2011;29(19):2689-95
86. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010;28(17):2817-23
87. Batchelor T, Mulholland P, Neyns B, et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared to lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Neuro Oncol 2010;12(Suppl 4):iv69-78
88. Neyns B, Sadones J, Chaskis C, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol 2011;103(3):491-501
89. Reardon DA, Vredenburgh JJ, Coan A, et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol 2011;105(3):621-7
90. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010;12(8):855-61
91. Reardon DA, Friedman HS, Yung WKA. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Onc; New Orleans, LA; 2004
92. Reardon DA, Egorin MJ, Desjardins A, et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009;115(10):2188-98
93. Yiin JJ, Hu B, Schornack PA, et al. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol Cancer Ther 2010;9(4):929-41
94. Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). ASCO Meeting Abstracts; 14 Jun 2010; Chicago; 2006
95. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003;88:169-77
96. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004;70(2):217-28 (Pubitemid 39545733)
97. Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev Anticancer Ther 2007;7(11):1537-60
98. Silva R, D'Amico G, Hodivala-Dilke KM, et al. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 2008;28(10):1703-13
99. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004;90(3):561-5 (Pubitemid 38297190)
100. Bello L, Francolini M, Marthyn P, et al. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery. Neurosurgery 2001;49(2):380-9; discussion 90
101. Albert JM, Cao C, Geng L, et al. Integrin alpha v beta 3 antagonist cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models. Int J Radiat Oncol Biol Phys 2006;65(5):1536-43 (Pubitemid 44425239)
102. Lathia JD, Gallagher J, Heddleston JM, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010;6(5):421-32
103. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008;26(34):5610-17
104. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(16):2712-18
105. Stupp R, Van den Bent MJ, Erridge SC, et al. Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomized, open label, controlled phase III trial (CENTRIC). Proc Am Soc Clin Oncol 2010;28(15s Suppl) :abstract TPS152
106. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997;49(2):123-31 (Pubitemid 27316530)
107. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000;18(4):708-15 (Pubitemid 30106600)
108. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2001;54(1):31-8 (Pubitemid 33089257)
109. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008;68(9):3077-80 discussion 80
110. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 2007;13(2 Pt 1):378-81 (Pubitemid 46225339)
111. Fan QW, Specht KM, Zhang C, et al. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res 2003;63(24):8930-8 (Pubitemid 38064073)
112. Papadopoulos KP, Markman B, Tabernero J, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2008;26:3510
113. Prasad G, Sottero T, Yang X, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011
114. Bagci-Onder T, Wakimoto H, Anderegg M, et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011;71(1):154-63
115. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI- 779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23(23):5294-30
116. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005;23(4):357-61 (Pubitemid 40980358)
117. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008;5(1):e8
118. Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007;26(13):1932-40 (Pubitemid 46474636)
119. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008;7(24):3805-9
120. Pitter KL, Galban CJ, Galban S, et al. Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma. PLoS One 2011;6(1):e14545
121. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4(12):937-47 (Pubitemid 39626217)
122. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study. J Clin Oncol 2006;24(22):3651-6 (Pubitemid 46630540)
123. Gilbert MR, Gaupp P, Liu V, et al. A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006. 24(18S Suppl): 1556
124. Wen PY, Cloughesy T, Kuhn J, et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02. ASCO Meeting Abstr 2009;27(15S):2006
125. Reardon DA, Vredenburgh JJ, Desjardins A, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol 2011;101(1):57-66
126. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007;61(2):153-61 (Pubitemid 46363842)
127. Fine HA, Kim L, Royce C, et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. 2005;2005:115S-S
128. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010;28(7):1168-74
129. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol 2010;12(6):608-13
130. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6(1):38-51 (Pubitemid 43054973)
131. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002;21(3):427-36 (Pubitemid 34123805)
132. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009;27(12):2052-8
133. Drappatz J, Raizer JJ, Schiff D, et al. A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). General Poster Session (Board #2G), ASCO 2011; Chicago, IL; 2011
134. Lavictoire SJ, Parolin DA, Klimowicz AC, et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 2003;278(7):5292-9 (Pubitemid 36801044)
135. Gopal U, Bohonowych JE, Lema-Tome C, et al. A novel extracellular Hsp90 mediated co-receptor function for LRP1 regulates EphA2 dependent glioblastoma cell invasion. PLoS ONE 2011;6(3):e17649
136. Sauvageot CM, Weatherbee JL, Kesari S, et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009;11(2):109-21
137. Laurent N, de Bouard S, Guillamo JS, et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 2004;3(2):129-36 (Pubitemid 39193687)
138. Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 2010;100(1):95-10
139. Bota D, Eroglu Z, Reardon DA, et al. Phase II trial of bortezomib and bevacizumab combination in recurrent glioblastoma. General Poster Session (Board #3F) at ASCO 2011; Chicago, IL; 2011
140. Wick W, Weller M, Weiler M, et al. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011;13(6):566-79
141. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011;13(4):437-46
142. Li Y, Guessous F, DiPierro C, et al. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 2009;8(2):376-85
143. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004;64(19):7011-21 (Pubitemid 39331011)
144. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444(7120):756-60 (Pubitemid 44949604)
145. Gilbert CA, Daou MC, Moser RP, et al. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 2010;70(17):6870-9
146. Bar EE, Chaudhry A, Lin A, et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007;25(10):2524-33 (Pubitemid 47582744)
147. Sai K, Wang S, Balasubramaniyan V, et al. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 2012;107(3):487-50
148. Bao S, Wu Q, Li Z, et al. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008;68(15):6043-8
149. Yoeli-Lerner M, Yiu GK, Rabinovitz I, et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005;20(4):539-50 (Pubitemid 41668639)
150. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002;62(1):200-7 (Pubitemid 34074005)
151. Coomber BL, Stewart PA, Hayakawa K, et al. Quantitative morphology of human glioblastoma multiforme microvessels: structural basis of blood-brain barrier defect. J Neurooncol 1987;5(4):299-30
152. Wolff NC, Richardson JA, Egorin M, et al. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003;101(12):5010-13 (Pubitemid 36857766)
153. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 2006;8(1):67-78 (Pubitemid 43154453)
154. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009;30(12):2302-18
155. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009;10(4):281-9
156. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005;102(21):7665-70 (Pubitemid 40741028)
157. Pillay V, Allaf L, Wilding AL, et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia 2009;11(5): 448-58 2p following 58
158. Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003;304(3):1085-92 (Pubitemid 36254421)
159. Abounader R, Laterra J. Scatter factor/ hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005;7(4):436-51 (Pubitemid 41555616)
160. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13(3):206-20 (Pubitemid 351318372)
161. Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-95 (Pubitemid 36554699)
162. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-14
163. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8(7):1277-80 (Pubitemid 20195640)
164. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-72
165. Ahluwalia MS, Wen PY. Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Rev Anticancer Ther 2011;11(5):653-6
166. Reardon DA, Galanis E, DeGroot JF, et al. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011;13(3):353-61
167. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011;28(4):334-40
168. ClinicalTrials.gov. Phase III Randomized Study of Concurrent Chemoradiotherapy and Adjuvant Temozolomide With Versus Without Bevacizumab in Patients With Newly Diagnosed Glioblastoma. Available from: http:// clinicaltrialsgov/ show/NCT00884741 NLM Identifier: NCT00884741 [Cited 10 Februry 2012]